{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:54:56Z","timestamp":1788324896117,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["J23201138"],"award-info":[{"award-number":["J23201138"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["22K09688, 23K19516"],"award-info":[{"award-number":["22K09688, 23K19516"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor (EGFR)-targeted photoimmunotherapy using cetuximab sarotalocan sodium (RM-1929) represents a novel therapeutic modality that induces selective tumor cell death and may influence the tumor immune microenvironment (TIME) in head and neck squamous cell carcinoma (HNSCC). However, its immunological consequences are not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated 25 patients with locoregional recurrent HNSCC who received RM-1929 photoimmunotherapy to evaluate treatment response, overall survival (OS), and safety. To explore TIME features, 14-marker multiplex immunohistochemistry was performed on pretreatment tumor samples from 14 patients, with 6 paired pre- and post-treatment samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Across 40 treatment cycles, the overall response rate was 77.5% (7 complete, 24 partial responses) with a median OS of 401 days. Treatment was generally well tolerated, with adverse events limited to expected local toxicities. Clinical responses were not explained by conventional clinicopathological factors or EGFR expression on tumor cells. In TIME analysis, responders exhibit significantly higher intratumoral CD39\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell density compared with non-responders. Longitudinal analyses revealed qualitative remodeling of the TIME after therapy, redistribution of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and increasement of PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      immune cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      RM-1929 photoimmunotherapy demonstrated local efficacy with limited adverse events. Distinct TIME characteristics and potential immune remodeling, involving CD39\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell, were observed. These observations provide a rationale for further investigation of photoimmunotherapy as a strategy to integrate local tumor ablation with systemic immune modulation in recurrent HNSCC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1814205","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:00:18Z","timestamp":1775800818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["EGFR-targeted photoimmunotherapy and its association with the immune microenvironment in locoregional recurrent head and neck squamous cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Koichi","family":"Yoshizawa","sequence":"first","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsujikawa","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]},{"name":"Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peesit","family":"Leelasawatsuk","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]},{"name":"Department of Otolaryngology Head and Neck Surgery, Prince of Songkla University","place":["Songkhla, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Mohamed","family":"Bedeir","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"van der Aar","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"de Martines","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saya","family":"Shibata","sequence":"additional","affiliation":[{"name":"SCREEN Holdings Co., Ltd.","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ogi","sequence":"additional","affiliation":[{"name":"SCREEN Holdings Co., Ltd.","place":["Kyoto, Japan"]},{"name":"Department of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Institute of Science Tokyo","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiyo","family":"Saburi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Mukudai","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Miyagawa-Hayashino","sequence":"additional","affiliation":[{"name":"Department of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Konishi","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Asakage","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Institute of Science Tokyo","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf018","article-title":"Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study","volume":"30","author":"Watanabe","year":"2025","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh308","article-title":"Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience","volume":"15","author":"Brockstein","year":"2004","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223887","article-title":"Head and neck squamous cell carcinoma with distant metastasis: a systematic review and meta-analysis","volume":"16","author":"Daloiso","year":"2024","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23861","article-title":"Prognostic value of level IV metastases from head and neck squamous cell carcinoma","volume":"38","author":"Hoch","year":"2016","journal-title":"Head Neck"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26885","article-title":"Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma","volume":"43","author":"Cognetti","year":"2021","journal-title":"Head Neck"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01960\u20136","article-title":"A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma","volume":"26","author":"Tahara","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-1\u201311","article-title":"The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications","volume":"1","author":"Zimmermann","year":"2006","journal-title":"Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c00104","article-title":"Photoinduced actin aggregation involves cell death: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy","volume":"19","author":"Sato","year":"2025","journal-title":"ACS Nano"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14425","article-title":"Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity","volume":"8","author":"Ogawa","year":"2017","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020\u2013001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future","volume":"9","author":"Alzeibak","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.03.037","article-title":"Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis","volume":"19","author":"Tsujikawa","year":"2017","journal-title":"Cell Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14591","article-title":"Prognostic significance of spatial immune profiles in human solid cancers","volume":"111","author":"Tsujikawa","year":"2020","journal-title":"Cancer Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27671","article-title":"Neutrophil-to-lymphocyte ratio associates with nutritional parameters, intratumoral immune profiles, and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma","volume":"46","author":"Morimoto","year":"2024","journal-title":"Head Neck"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591\u20137","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2022","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11413","article-title":"Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma","volume-title":"Oncotarget","author":"Bossi","year":"2016"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22930","article-title":"Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines","volume":"50","author":"Peng","year":"2018","journal-title":"Lasers Surg Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01274-z","article-title":"WNT\/\u03b2-catenin regulatory roles on PD-(L)1 and immunotherapy responses","volume":"24","author":"Mortezaee","year":"2024","journal-title":"Clin Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1376498","article-title":"A novel nomogram model based on Ki-67 characteristic expression to predict prognosis in head and neck squamous cell carcinoma","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2008.12","article-title":"Biology of HIF-1\u03b1","volume":"15","author":"Weidemann","year":"2008","journal-title":"Cell Death Differ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6740","DOI":"10.1038\/s41467-022-34495-z","article-title":"Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hed.70014","article-title":"Safety and efficacy findings from a phase Ib\/II study of ASP-1929 photoimmunotherapy with pembrolizumab in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"48","author":"Cognetti","year":"2026","journal-title":"Head Neck"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16427","article-title":"Antitumor host immunity enhanced by near-infrared photoimmunotherapy","volume":"116","author":"Fukushima","year":"2025","journal-title":"Cancer Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/intimm\/dxaa037","article-title":"Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity","volume":"33","author":"Kobayashi","year":"2021","journal-title":"Int Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/intimm\/dxad042","article-title":"Near-infrared photoimmunotherapy and anti-cancer immunity","volume":"36","author":"Nakajima","year":"2024","journal-title":"Int Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41419-024-07178\u20134","article-title":"Nicotine-induced CHRNA5 activation modulates CES1 expression, impacting head and neck squamous cell carcinoma recurrence and metastasis via MEK\/ERK pathway","volume":"15","author":"Feng","year":"2024","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225733","article-title":"Relationship between tumor mutational burden, PD-L1, patient characteristics, and response to immune checkpoint inhibitors in head and neck squamous cell carcinoma","volume":"13","author":"Burcher","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy060","article-title":"Tobacco smoking-associated alterations in the immune microenvironment of squamous cell carcinomas","volume":"110","author":"Desrichard","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101017","article-title":"Hypoxia-induced therapy resistance: available hypoxia-targeting strategies and current advances in head and neck cancer","volume":"14","author":"Codony","year":"2021","journal-title":"Transl Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cplu.202000338","article-title":"Theoretical and experimental studies on the near\u2010infrared photoreaction mechanism of a silicon phthalocyanine photoimmunotherapy dye: photoinduced hydrolysis by radical anion generation","volume":"85","author":"Kobayashi","year":"2020","journal-title":"Chempluschem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.8b00565","article-title":"Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy","volume":"4","author":"Sato","year":"2018","journal-title":"ACS Cent Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13378","article-title":"Near-infrared uncaging or photosensitizing dictated by oxygen tension","volume":"7","author":"Anderson","year":"2016","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144\u20136","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16\u20132684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09\u20132891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712\u2013100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1200\/jco.2024.42.16_suppl.6083","article-title":"Recent safety and efficacy findings from a phase 1b\/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC)","volume":"42","author":"Cognetti","year":"2024","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103501","article-title":"Near infrared photoimmunotherapy for cancers: a translational perspective","volume":"70","author":"Maruoka","year":"2021","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1814205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:00:20Z","timestamp":1775800820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1814205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1814205"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1814205","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1814205"}}